Lumacaftor is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF). Lumacaftor may act to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, the defective cell membrane protein responsible for the progression of CF. Lumacaftor defects in the CFTR protein affect the transport of chloride and other ions across cells, and lead to the accumulation of thick, sticky mucus in the lungs of patients with CF. This mucus fosters chronic infection and inflammation, and results in irreversible lung damage.https://www.bocsci.com/lumacaftor-cas-936727-05-8-item-79818.html
BOC Sciences is the chemistry division of Creative Dynamics Inc. headquartered in New York, USA. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and ce...
View more >>
Basic Information
Business Type: Manufacturer
Product/Service (We Buy): 101 - 500 People
Year Established: 2005
Number of Employees: 101 - 500 People
Trade & Market
Main Markets: North America,Southeast Asia,Mid East,South America,Africa,Eastern Asia,Eastern Europe,Oceania,Western Europe
QA/QC: 0
Number of R&D Staff: 0
Total Annual Sales Volume: US$5 Million - US$10 Million
United States
